ArticleDiscover oncology2026
DNA methylation driven genes shape prognosis and tumor immune landscape in rectal cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundDNA methylation alterations play a crucial role in rectal cancer development. This study identifies and characterizes DNA methylation-driven genes in the TCGA-READ cohort, constructs a prognostic model, and validates its robustness and biological relevance in independent external cohorts.
methodsUsing TCGA-READ (n = 160) as the discovery cohort, we identified 490 methylation-driven genes via MethylMix analysis. A LASSO-derived prognostic model was constructed integrating expression of CCNI2, LINC00899, and ST6GALNAC1. Model performance was assessed by Kaplan–Meier analysis, time-dependent ROC, calibration, and decision curve analysis. Mechanistic insights were explored using differential expression, PPI network analysis, GSEA, and immune infiltration estimation. External validation of the prognostic model was performed in the independent dataset GSE103479 (n = 155). To address gene expression and functional relevance, expression differences for CCNI2, LINC00899, and ST6GALNAC1 were examined in external datasets (GSE71187 and GSE87211), and correlation-based, cross-dataset-averaged GSEA was conducted against MSigDB GO/KEGG/Hallmark collections.
resultsThe three-gene model stratified TCGA-READ patients into high- and low-risk groups with progressive AUCs of 0.636, 0.714, and 0.898 at 1, 3, and 5 years. High-risk tumors showed reduced expression of multiple protective genes (hub: SULF1), depletion of negative regulators of oncogenic pathways, and reduced cytotoxic immune infiltration. In GSE103479, external validation demonstrated consistent risk stratification trends and supported broader applicability. Gene-specific analyses revealed CCNI2 correlated with proliferation and antigen processing pathways; LINC00899 associated with metabolic reprogramming (oxidative phosphorylation, glycolysis); ST6GALNAC1 linked to epithelial maintenance and fatty acid metabolism.
conclusionsA methylation-driven 3-gene signature provides prognostic value in READ and is supported by independent-cohort validation and external bioinformatics evidence for gene expression and functional relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.